Chlorprothixene Hydrochloride Injection

This product is a thioxanthene antipsychotic drug, which can improve mental disorders by blocking postsynaptic dopamine receptors in the brain, inhibit the ascending activation system of the brainstem reticular formation, cause sedation, and inhibit the medulla chemoreceptor area to exert an antiemetic effect. This product has weak anti-adrenergic and anticholinergic effects, and has antidepressant and antianxiety effects.

The main ingredient of this product is chlorprothixene hydrochloride, and its chemical name is: (Z) N, N-dimethyl-3-(2-chloro-9H-thioxanthenyl)-1-propylamine hydrochloride.

This product is a colorless clear liquid.

Used for acute and chronic schizophrenia, and for mental disorders accompanied by psychomotor agitation, anxiety, and depression symptoms.

For patients who are excited, agitated and uncooperative, 30 mg can be injected intramuscularly once, 2 to 6 times a day.

Anticholinergic symptoms include dizziness, drowsiness, weakness, postural hypotension, palpitations, dry mouth, constipation, blurred vision, and dysuria. Extrapyramidal reactions may occur at high doses, such as tremor, rigidity, salivation, bradykinesia, akathisia, and acute dystonia. Long-term and large-scale use may cause tardive dyskinesia. It may cause an increase in plasma prolactin concentration, and possible related symptoms include: galactorrhea, gynecomastia, menstrual disorders, and amenorrhea. It may cause liver damage and granulocytopenia. It may occasionally cause epilepsy. Allergic rashes and malignant syndrome are occasionally seen. It may cause local redness, swelling, pain, and nodules at the injection site.

Basal ganglia lesions, Parkinson's disease, Parkinson's syndrome, bone marrow suppression, glaucoma, urinary retention, coma and allergic to this product.

1. This product can enhance the efficacy of central nervous system depressants such as inhaled general anesthetics or intravenous general anesthetics such as barbiturates. When used together, the dosage of central nervous system depressants should be reduced to 1/4~1/2 of the usual dosage. 2. This product can reduce the effect of amphetamine when used in combination. 3. When used in combination with gastric acid suppressants or laxatives, the absorption of this product can be reduced. 4. This product can lower the seizure threshold and weaken the effect of anticonvulsants. It is not suitable for patients with epilepsy. 5. When this product is used in combination with anticholinergic drugs, the efficacy can be mutually enhanced. 6. When this product is used in combination with adrenaline, due to the blockage of α receptor activity and the dominance of β receptor activity, a drop in blood pressure may occur. <br

Keep in dark place and sealed

2ml:30mg